Recent News

• 04.25.2025 - Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
• 03.25.2025 - Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
• 03.24.2025 - Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
• 02.25.2025 - Bolt Biotherapeutics to Participate in Upcoming March Conferences
• 02.11.2025 - Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
• 12.30.2024 - Jakob Dupont, M.D.
• 11.12.2024 - Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Recent Filings

• 04.16.2025 - PRE 14A Other preliminary proxy statements
• 04.16.2025 - 8-K Current report
• 04.15.2025 - DEF 14A Other definitive proxy statements
• 03.24.2025 - 8-K Current report
• 03.24.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.24.2025 - EX-99.1 EX-99.1
• 03.24.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 01.03.2025 - 8-K Current report
• 12.23.2024 - 8-K Current report
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors